|
gptkbp:instance_of
|
gptkb:Ophthalmology
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:available_on
|
generic version
|
|
gptkbp:average_temperature
|
room temperature
|
|
gptkbp:brand
|
gptkb:Lumigan
|
|
gptkbp:category
|
Category C
|
|
gptkbp:class
|
prostaglandin analogs
|
|
gptkbp:clinical_trial
|
Phase III trials
|
|
gptkbp:clinical_use
|
ophthalmology
|
|
gptkbp:community_service
|
safety not established
|
|
gptkbp:contraindication
|
hypersensitivity to bimatoprost
|
|
gptkbp:dosage_form
|
gptkb:Software_Solutions
|
|
gptkbp:drug_interactions
|
other eye medications
systemic medications
|
|
gptkbp:duration
|
24 hours
|
|
gptkbp:effective_date
|
gptkb:2001
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:cream
newer formulations available
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lumigan
|
|
gptkbp:indication
|
gptkb:ocular_hypertension
|
|
gptkbp:ingredients
|
gptkb:bimatoprost
|
|
gptkbp:lactation
|
caution advised
|
|
gptkbp:manufacturer
|
gptkb:Allergan
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:patient_population
|
instructions for use
|
|
gptkbp:premiered_on
|
4 hours
|
|
gptkbp:price
|
varies by pharmacy
|
|
gptkbp:provides_guidance_on
|
gptkb:American_Academy_of_Ophthalmology
gptkb:European_Glaucoma_Society
follow prescribing information
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:research_focus
|
patient quality of life
cost-effectiveness
long-term effects
comparative effectiveness
|
|
gptkbp:route_of_administration
|
topical
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
dry eyes
eye irritation
hyperemia
periorbital skin pigmentation
changes in eyelash growth
eyelash darkening
iris pigmentation
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:used_for
|
treatment of glaucoma
|
|
gptkbp:bfsParent
|
gptkb:Latisse
|
|
gptkbp:bfsLayer
|
6
|